\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ ast\\,\\ alt\\,\\ alk\\ phos\\,\\ and\\ total\\ bilirubin\\.\ \(0\)\
\-\ no\\ treatment\\ or\\ followup\\ is\\ necessary\\ in\\ this\\ case\\.\ \(0\)\
\-\ discontinuous\\ peripheral\\ pooling\\ of\\ contrast\\ enhancement\\ in\\ the\\ arterial\\ phase\\ with\\ progressive\\ filling\\ seen\\ in\\ the\\ portal\\ venous\\ phase\\ and\\ prolonged\\ enhancement\\ of\\ the\\ lesion\\ in\\ delayed\\ images\\ on\\ a\\ three\\ phase\\ enhanced\\ liver\\ ct\\.\ \(0\)\
\-\ liver\\ hemangioma\ \(2\)\
\-\ ddx\\ of\\ hypodense\\ liver\\ lesion\\:\ \(0\)\
\-\ \\â\\€\\¢\\	cavernous\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\	metastatic\\ disease\\ \ \(0\)\
\-\ \\â\\€\\¢\\	hcc\ \(0\)\
\-\ \\â\\€\\¢\\	focal\\ nodular\\ hyperplasia\ \(0\)\
\-\ \\â\\€\\¢\\	hepatic\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	fibrolamellar\\ carcinoma\ \(0\)\
\-\ \\â\\€\\¢\\	lymphoma\ \(0\)\
\-\ \\â\\€\\¢\\	hepatic\\ adenoma\ \(0\)\
\-\ 38\\ y\\/o\\ woman\\ to\\ evaluate\\ liver\\ lesion\\.\ \(1\)\
\-\ note\\:\\ \\ these\\ are\\ dynamic\\ enhanced\\ images\\ that\\ confirm\\ benign\\ hemangioma\\.\\ \\ the\\ discontinuous\\ peripheral\\ pooling\\ of\\ contrast\\ enhancement\\ in\\ the\\ arterial\\ phase\\ \\-\\ followed\\ by\\ progressive\\ filling\\ seen\\ in\\ the\\ portal\\ venous\\ phase\\ \\-\\ with\\ prolonged\\ enhancement\\ of\\ the\\ lesion\\ on\\ the\\ delayed\\ images\\ \\-\\ is\\ classic\\ for\\ hemangioma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ phase\\:\\ 0\\.13580161751249178\ \(0\)\
\-\ hemangioma\\:\\ 0\\.10319746351898333\ \(0\)\
\-\ discontinuous\\:\\ 0\\.09283254425555655\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.08470347846464259\ \(0\)\
\-\ pooling\\:\\ 0\\.08446714954736434\ \(0\)\
\-\ liver\\:\\ 0\\.07962760840088443\ \(0\)\
\-\ enhancement\\:\\ 0\\.06190510178710908\ \(0\)\
\-\ prolonged\\:\\ 0\\.06133584195878977\ \(0\)\
\-\ portal\\:\\ 0\\.060784193384191734\ \(0\)\
\-\ arterial\\:\\ 0\\.05054519741530637\ \(0\)\
\-\ enhanced\\:\\ 0\\.04941166384799959\ \(0\)\
\-\ hepatic\\:\\ 0\\.04822289664602719\ \(0\)\
\-\ lesion\\:\\ 0\\.047042033135147425\ \(0\)\
\-\ delayed\\:\\ 0\\.046999734381961894\ \(0\)\
\-\ filling\\:\\ 0\\.046489729949761256\ \(0\)\
\-\ progressive\\:\\ 0\\.0456410691222068\ \(0\)\
\-\ venous\\:\\ 0\\.041916021871042285\ \(0\)\
\-\ peripheral\\:\\ 0\\.041782882729920506\ \(0\)\
\-\ fibrolamellar\\:\\ 0\\.04173284523210297\ \(0\)\
\-\ hcc\\:\\ 0\\.03809097698390914\ \(0\)\
\-\ dynamic\\:\\ 0\\.03729514566190655\ \(0\)\
\-\ \\-\\:\\ 0\\.03712963091976413\ \(0\)\
\-\ bilirubin\\:\\ 0\\.03481051876916792\ \(0\)\
\-\ alk\\:\\ 0\\.033695115050523\ \(0\)\
\-\ phos\\:\\ 0\\.033695115050523\ \(0\)\
\-\ images\\:\\ 0\\.03322832213410853\ \(0\)\
\-\ ast\\:\\ 0\\.03135899428426257\ \(0\)\
\-\ alt\\:\\ 0\\.03135899428426257\ \(0\)\
\-\ hypodense\\:\\ 0\\.030762422614359346\ \(0\)\
\-\ 38\\:\\ 0\\.030762422614359346\ \(0\)\
\-\ ddx\\:\\ 0\\.03048279277542114\ \(0\)\
\-\ confirm\\:\\ 0\\.0293892588196751\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.028448298905259507\ \(0\)\
\-\ followup\\:\\ 0\\.027562972807918938\ \(0\)\
\-\ cavernous\\:\\ 0\\.026780325405722172\ \(0\)\
\-\ contrast\\:\\ 0\\.025848320091998722\ \(0\)\
\-\ necessary\\:\\ 0\\.02557486826063556\ \(0\)\
\-\ total\\:\\ 0\\.024862972884569165\ \(0\)\
\-\ nodular\\:\\ 0\\.02421898518318859\ \(0\)\
\-\ adenoma\\:\\ 0\\.024111448323013596\ \(0\)\
\-\ evaluate\\:\\ 0\\.023339366609845088\ \(0\)\
\-\ seen\\:\\ 0\\.022819292095509328\ \(0\)\
\-\ note\\:\\ 0\\.02228422653717426\ \(0\)\
\-\ classic\\:\\ 0\\.022123343775730216\ \(0\)\
\-\ benign\\:\\ 0\\.019926015993467577\ \(0\)\
\-\ three\\:\\ 0\\.019463677218560207\ \(0\)\
\-\ followed\\:\\ 0\\.019357269401207917\ \(0\)\
\-\ in\\:\\ 0\\.0170836714921725\ \(0\)\
\-\ lymphoma\\:\\ 0\\.016501342124253283\ \(0\)\
\-\ focal\\:\\ 0\\.016489821649583798\ \(0\)\
\-\ carcinoma\\:\\ 0\\.016364376148755855\ \(0\)\
\-\ y\\/o\\:\\ 0\\.015990736687970547\ \(0\)\
\-\ cyst\\:\\ 0\\.01551602118936556\ \(0\)\
\-\ \\:\\:\\ 0\\.015273983999873854\ \(0\)\
\-\ these\\:\\ 0\\.015025977648363786\ \(0\)\
\-\ metastatic\\:\\ 0\\.014534522997406017\ \(0\)\
\-\ woman\\:\\ 0\\.013337182077627746\ \(0\)\
\-\ case\\:\\ 0\\.012631786708562642\ \(0\)\
\-\ treatment\\:\\ 0\\.011686601078384373\ \(0\)\
\-\ that\\:\\ 0\\.009972842760532591\ \(0\)\
\-\ on\\:\\ 0\\.00978231097791119\ \(0\)\
\-\ by\\:\\ 0\\.009613992589492398\ \(0\)\
\-\ disease\\:\\ 0\\.009437415819025028\ \(0\)\
\-\ normal\\:\\ 0\\.00905143550404798\ \(0\)\
\-\ ct\\:\\ 0\\.008076376036432723\ \(0\)\
\-\ are\\:\\ 0\\.007870769408983796\ \(0\)\
\-\ is\\:\\ 0\\.007598524032226023\ \(0\)\
\-\ the\\:\\ 0\\.007472934308304097\ \(0\)\
\-\ or\\:\\ 0\\.006767045601106132\ \(0\)\
\-\ this\\:\\ 0\\.006494170360230629\ \(0\)\
\-\ no\\:\\ 0\\.0058138118290797436\ \(0\)\
\-\ \\,\\:\\ 0\\.005487366192917988\ \(0\)\
\-\ for\\:\\ 0\\.004926406409748075\ \(0\)\
\-\ of\\:\\ 0\\.0039359392161482576\ \(0\)\
\-\ to\\:\\ 0\\.0028855953273174747\ \(0\)\
\-\ a\\:\\ 0\\.0026797283906662248\ \(0\)\
\-\ and\\:\\ 0\\.0024325541315164657\ \(0\)\
\-\ with\\:\\ 0\\.0015811375147282397\ \(0\)\
\-\ \\.\\:\\ 0\\.0014391703823248491\ \(0\)\
